Correlation Between Entrada Therapeutics and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Entrada Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entrada Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Entrada Therapeutics and Molecular Partners AG, you can compare the effects of market volatilities on Entrada Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entrada Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entrada Therapeutics and Molecular Partners.

Diversification Opportunities for Entrada Therapeutics and Molecular Partners

0.36

Correlation Coefficient

Entrada Therapeutics  Molecular Partners

Weak diversification

The 3 months correlation between Entrada and Molecular is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Entrada Therapeutics and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Entrada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entrada Therapeutics are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Entrada Therapeutics i.e., Entrada Therapeutics and Molecular Partners go up and down completely randomly.

Pair Corralation between Entrada Therapeutics and Molecular Partners

Given the investment horizon of 90 days Entrada Therapeutics is expected to generate 0.93 times more return on investment than Molecular Partners. However, Entrada Therapeutics is 1.08 times less risky than Molecular Partners. It trades about 0.04 of its potential returns per unit of risk. Molecular Partners AG is currently generating about 0.02 per unit of risk. If you would invest  1,523  in Entrada Therapeutics on August 31, 2024 and sell it today you would earn a total of  466.00  from holding Entrada Therapeutics or generate 30.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Entrada Therapeutics  vs.  Molecular Partners AG

Entrada Therapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Entrada Therapeutics and Molecular Partners

The main advantage of trading using opposite Entrada Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entrada Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Entrada Therapeutics and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.